Advertisement
Journal Home
Search for

Volume 46, Issue 1, Pages 56-71 (January 2010)


View previous. 9 of 28 View next.

ONCOPOOL – A European database for 16,944 cases of breast cancer

R.W. BlameyaCorresponding Author Informationemail address, B. Hornmark-Stenstamab, G. Ballc, M. Blichert-Tofta, L. Cataliottia, A. Fourqueta, J. Geed, K. Hollia, R. Jakesza, M. Kerina, R. Mansela, R. Nicholsonad, T. Pienkowskia, S. Pindere, M. Sundquista, M. van de Vijvera, I. Ellise

Received 9 June 2009; received in revised form 9 July 2009; accepted 9 September 2009. published online 07 October 2009.

Abstract 

ONCOPOOL is a retrospectively compiled database of primary operable invasive breast cancers treated in the 1990s in 10 European breast cancer Units. Sixteen thousand and nine hundred and forty four cases were entered, with tumours less than 5cm diameter in women aged 70 or less (mean age 55).

Data

Data were date of birth, mode of diagnosis, pathology (size, lymph node status, grade, type, lympho-vascular invasion and hormone receptor) and therapies and outcome measures: first local, regional or distant recurrences, contralateral primary, date and cause of death.

Tumour characteristics

Mean diameter 1.8cm, 66% lymph node negative, 24% 1–3 lymph nodes involved and 10% had 4 or more involved. Grade 1, 29%; Grade 2, 41%; and Grade 3, 30%. Polynomial relationships were established between grade, stage and size.

Seventy-five percent were oestrogen receptor (ER) positive. ER closely related to grade.

Outcomes

Overall Survival was 89% at 5years from diagnosis, 80% 10years and 73% 15years; Breast Cancer-Specific survivals were 91%, 84% and 79%.

Survival strongly related to the Nottingham Prognostic Index (NPI).

Cases detected at screening had 84% 10-year survival, those presenting symptomatically 76%.

ER positive cases treated with adjuvant hormone therapy had a reduction in risk of death of 13% over those not receiving adjuvant therapy (p=0.000). ER negative cases treated with chemotherapy showed a risk reduction of 23% over those not receiving chemotherapy (p=0.000).

On behalf of ONCOPOOL Consortium at Breast Institute, Nottingham City Hospital, NG5 1PB, UK

Corresponding Author InformationCorresponding author: Tel.: +44 (0)115 9625707; fax: +44 (0)115 9627765.

a Co-applicant for grant support.

b Clinical QA.

c Data analyst.

d Endocrine QA.

e Pathology QA.

PII: S0959-8049(09)00681-9

doi:10.1016/j.ejca.2009.09.009


View previous. 9 of 28 View next.